Bleeding In Thrombocytopenia Explained

Launched by SANQUIN-LUMC J.J VAN ROOD CENTER FOR CLINICAL TRANSFUSION RESEARCH · Apr 12, 2018

Keywords

ClinConnect Summary

This clinical trial, titled "Bleeding In Thrombocytopenia Explained," is looking into the factors that can lead to bleeding in patients with blood cancers, specifically during intensive treatments like chemotherapy or stem cell transplants. Researchers want to identify certain clinical signs and blood markers that could help predict when a patient might experience significant bleeding due to low platelet counts, a condition known as thrombocytopenia.

To participate in the study, you need to be at least 18 years old and currently admitted to the hospital for treatment related to blood cancers. This includes patients who are likely to have low platelet counts for at least five days and may receive platelet transfusions to help prevent bleeding. The trial is open to all genders and is currently recruiting participants. If you qualify, you can expect to undergo assessments that will help researchers gather valuable information about bleeding risks in patients receiving intensive treatment for blood disorders.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Inclusion criteria are mentioned below and differ for part A and B of the study.
• • Admission in the hospital. (part A and B)
• • Age ≥ 18 years. (part A and B)
• AND:
• • • Hemato-oncology patient, including MDS and AA, admitted for treatment (chemotherapy, SCT) who is (expected to become) thrombocytopenic with platelet counts of \< 50 for expected at least 5 days and who will possibly be treated with one or more prophylactic platelet transfusions. (part A and B)
• OR:
• • • Hemato-oncology patient who had previous intensive chemotherapy or stem cell transplantation and who is admitted to the hematology ward for disease or treatment related events or complications. (part A only)
• Exclusion Criteria:
• • • Patients with myeloproliferative disorders.